HomeAI · summaries
Storia in 3 fonti
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic dysfunction-associated steatotic liver disease.Researchers reported new data from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials of survodutide (Boehringer Ingelheim/Zealand Pharma) at the American Diabetes Association Scientific
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic…
- ·
morningstar.com
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
- ·
medpagetoday.com
Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
Roughly one in five patients ditched survodutide due to adverse events